drugset

drugset / Trial / NCT02205372

Safety, Tolerability and Pharmacokinetic Study of MT-3995 at a Low Dose in Subjects With Diabetic Nephropathy

NCT02205372 ↗

Phase 1/2 Completed 31 enrolled Tanabe Pharma Corporation

RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of this study is to evaluate safety, tolerability and pharmacokinetics of MT-3995 in Subjects with Diabetic Nephropathy.

Timeline

Start: 2014-07
Primary completion: 2015-08
Completion: 2015-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	MT-3995	Small molecule	—	—

Indications